Last reviewed · How we verify
NCT04515888: STATICBREAST
Evaluation of the Prevalence of Pelvic Static Disorders in Women With Localized Breast Cancer
trial testing PFDI-20 / PFIQ-7 questionnaires in Breast Cancer in 246 participants. Completed in 6 July 2021.
12 February 2021
Quick facts
| Lead sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 246 |
| Start date | 18 September 2020 |
| Primary completion | 12 February 2021 |
| Estimated completion | 6 July 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- PFDI-20 / PFIQ-7 questionnaires
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle — full company profile →
Who can join
50 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, investigator propose to assess the prevalence of pelvic static disorders in women undergoing adjuvant hormone therapy for localized breast cancer and to assess the overall quality of life in these patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04515888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Institut du Cancer de Montpellier - Val d'Aurelle trials
Trials by the same sponsor.
- NCT07523152 — Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With H · NA · not yet recruiting
- NCT07198971 — Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addicti · NA · recruiting
- NCT07043543 — Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11) · NA · not yet recruiting
- NCT07441941 — Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup · recruiting
- NCT06382818 — Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04515888 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut du Cancer de Montpellier - Val d'Aurelle
- Last refreshed: 4 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04515888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing